By Administrator_ India
Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of the Johnson & Johnson COVID-19 vaccine, by $23 million.
The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.
Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca ( Plc’s COVID-19 vaccine bulk drug substance.
On Thursday, oil prices remained at 13-week highs, supported by strong demand in the world's largest consumer, the United States, Read more
The dollar was down on Thursday morning in Asia, alongside the euro. Investors are digesting the U.S. doubts that Russia Read more
Asian stock markets were generally weaker in holiday-thinned trading on Monday, as uncertainty over the economic impact of the Omicron Read more
By Administrator_India Capital Sands The U.S. government told its citizens to leave India as soon as possible because of the Read more